227 related articles for article (PubMed ID: 24162384)
21. The Role of CD34 and D2-40 in the Differentiation of Dermatofibroma and Dermatofibrosarcoma Protuberans.
Sadullahoğlu C; Dere Y; Atasever TR; Öztop MT; Karaaslan Ö
Turk Patoloji Derg; 2017; 1(1):223-227. PubMed ID: 28832078
[TBL] [Abstract][Full Text] [Related]
22. Dermatofibroma and dermatofibrosarcoma protuberans: an immunohistochemical study reveals distinctive antigenic profiles.
Hsi ED; Nickoloff BJ
J Dermatol Sci; 1996 Jan; 11(1):1-9. PubMed ID: 8867761
[TBL] [Abstract][Full Text] [Related]
23. Collagen triple helix repeat containing-1 in the differential diagnosis of dermatofibrosarcoma protuberans and dermatofibroma.
Wang L; Xiang YN; Zhang YH; Tu YT; Chen HX
Br J Dermatol; 2011 Jan; 164(1):135-40. PubMed ID: 20849518
[TBL] [Abstract][Full Text] [Related]
24. Immunohistochemical analysis of platelet-derived growth factor and its receptors in fibrohistiocytic tumors.
Taniuchi K; Yamada Y; Nonomura A; Takehara K
J Cutan Pathol; 1997 Aug; 24(7):393-7. PubMed ID: 9274955
[TBL] [Abstract][Full Text] [Related]
25. A study of CD117 expression in dermatofibrosarcoma protuberans and cellular dermatofibroma.
Labonte S; Hanna W; Bandarchi-Chamkhaleh B
J Cutan Pathol; 2007 Nov; 34(11):857-60. PubMed ID: 17944726
[TBL] [Abstract][Full Text] [Related]
26. Dermatofibrosarcoma protuberans treated with Mohs surgery. A case with CD34 immunostaining variability.
Garcia C; Viehman G; Hitchcock M; Clark RE
Dermatol Surg; 1996 Feb; 22(2):177-9. PubMed ID: 8608381
[TBL] [Abstract][Full Text] [Related]
27. Apolipoprotein D in CD34-positive and CD34-negative cutaneous neoplasms: a useful marker in differentiating superficial acral fibromyxoma from dermatofibrosarcoma protuberans.
Lisovsky M; Hoang MP; Dresser KA; Kapur P; Bhawan J; Mahalingam M
Mod Pathol; 2008 Jan; 21(1):31-8. PubMed ID: 17885669
[TBL] [Abstract][Full Text] [Related]
28. CD44 and hyaluronate in the differential diagnosis of dermatofibroma and dermatofibrosarcoma protuberans.
Calikoglu E; Augsburger E; Chavaz P; Saurat JH; Kaya G
J Cutan Pathol; 2003 Mar; 30(3):185-9. PubMed ID: 12641778
[TBL] [Abstract][Full Text] [Related]
29. Desmin and CD34 positivity in cellular fibrous histiocytoma: an immunohistochemical analysis of 100 cases.
Volpicelli ER; Fletcher CD
J Cutan Pathol; 2012 Aug; 39(8):747-52. PubMed ID: 22775584
[TBL] [Abstract][Full Text] [Related]
30. Plaque-like CD34-positive dermal fibroma ("medallion-like dermal dendrocyte hamartoma"): clinicopathologic, immunohistochemical, and molecular analysis of 5 cases emphasizing its distinction from superficial, plaque-like dermatofibrosarcoma protuberans.
Kutzner H; Mentzel T; Palmedo G; Hantschke M; Rütten A; Paredes BE; Schärer L; Guillen CS; Requena L
Am J Surg Pathol; 2010 Feb; 34(2):190-201. PubMed ID: 20061935
[TBL] [Abstract][Full Text] [Related]
31. Neurofibromatous changes in dermatofibrosarcoma protuberans: a potential pitfall in the diagnosis of a serious cutaneous soft tissue neoplasm.
Kovarik CL; Hsu MY; Cockerell CJ
J Cutan Pathol; 2004 Aug; 31(7):492-6. PubMed ID: 15239679
[TBL] [Abstract][Full Text] [Related]
32. Cellular digital fibromas: distinctive CD34-positive lesions that may mimic dermatofibrosarcoma protuberans.
McNiff JM; Subtil A; Cowper SE; Lazova R; Glusac EJ
J Cutan Pathol; 2005 Jul; 32(6):413-8. PubMed ID: 15953374
[TBL] [Abstract][Full Text] [Related]
33. Flow-cytometric DNA analysis in cutaneous fibrohistiocytic tumors.
Okita H; Ohtsuka T; Yamazaki S
Dermatology; 2003; 207(4):357-61. PubMed ID: 14657626
[TBL] [Abstract][Full Text] [Related]
34. High proliferative activity excludes dermatofibroma: report of the utility of MIB-1 in the differential diagnosis of selected fibrohistiocytic tumors.
Hanly AJ; Jordà M; Elgart GW; Badiavas E; Nassiri M; Nadji M
Arch Pathol Lab Med; 2006 Jun; 130(6):831-4. PubMed ID: 16740036
[TBL] [Abstract][Full Text] [Related]
35. Low-affinity nerve growth factor receptor (p75) in dermatofibrosarcoma protuberans and other nonneural tumors: a study of 1,150 tumors and fetal and adult normal tissues.
Fanburg-Smith JC; Miettinen M
Hum Pathol; 2001 Sep; 32(9):976-83. PubMed ID: 11567228
[TBL] [Abstract][Full Text] [Related]
36. CD34+ pigmented fibrous proliferations: the morphologic overlap between pigmented dermatofibromas and Bednar tumors.
McAllister JC; Recht B; Hoffman TE; Sundram UN
Am J Dermatopathol; 2008 Oct; 30(5):484-7. PubMed ID: 18806495
[TBL] [Abstract][Full Text] [Related]
37. Immunohistochemical characterization of dermatofibrosarcoma protuberans with practical applications for diagnosis and treatment.
Haycox CL; Odland PB; Olbricht SM; Piepkorn M
J Am Acad Dermatol; 1997 Sep; 37(3 Pt 1):438-44. PubMed ID: 9308560
[TBL] [Abstract][Full Text] [Related]
38. Diagnostic utility of ERG immunostaining in dermatofibroma.
Yamada Y; Ichiki T; Susuki Y; Yamada-Nozaki Y; Tateishi Y; Furue M; Oda Y
J Clin Pathol; 2023 Aug; 76(8):536-540. PubMed ID: 35318257
[TBL] [Abstract][Full Text] [Related]
39. The expression levels of thrombospondin-1 in dermatofibroma and dermatofibrosarcoma protuberans.
Maekawa T; Jinnin M; Ohtsuki M; Ihn H
Eur J Dermatol; 2011; 21(4):534-8. PubMed ID: 21697041
[TBL] [Abstract][Full Text] [Related]
40. A unique biphasic variant of cutaneous fibrous histiocytoma with a storiform pattern and intralesional pigmented melanocytes: "storiform melano-fibrous histiocytoma".
Nair V; Weinreb I; MacNeil N; Szollosi Z; Chetty R; Ghazarian D
Eur J Dermatol; 2008; 18(3):332-6. PubMed ID: 18474466
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
